CTSO: Q1 2020: CTSO Nabs FDA breakthrough designation and European approval for ticagrelor removal, Q1 Product revenue sets new record, Moving PT to $15/share
Cytosorbents is engaged in critical care immunotherapy, investigating and commercializing its CytoSorb blood purification technology to reduce uncontrolled inflammation in hospitalized patients around the world, to prevent or treat multiple organ failure in life-threatening illnesses and cardiac surgery. CytoSorb, the company's primary product, is approved in the European Union as an extracorporeal cytokine filter and is designed to reduce the cytokine storm that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis. CytoSorb is used during and after cardiac surgery.
Zacks Investment Research is a Chicago based firm with over 30 years of experience in providing institutional and individual investors with the analytical tools and financial information necessary to the success of their investment process.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.